Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.

Valeria SantiniPierre FenauxAristoteles GiagounidisUwe PlatzbeckerAlan F ListTorsten HaferlachJim ZhongChengqing WuKonstantinos MavrommatisC L BeachKyle J MacBethAntonio Almeida

Published in: Leukemia (2020)

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
multiple myeloma
gene expression
stem cell transplantation
copy number
low dose
high dose
patient reported